Breast Cancer Research and Treatment

, Volume 52, Issue 1–3, pp 261–288 | Cite as

The relationship between prognostic and predictive factors in the management of breast cancer

  • I. Craig Henderson
  • Anthony J. Patek


The discovery of new prognostic factors proceeds at a much more rapid pace than our knowledge of how to properly utilize this information in the management of patients with breast cancer, especially those with early breast cancer that has not metastasized to regional lymph nodes. Prognostic factors provide information on how the patient is likely to do regardless of treatment. Predictive factors provide information on whether a patient is likely to benefit from therapy. Most factors identified to date provide prognostic information, but relatively few provide information that is truly helpful in making a therapeutic decision in the management of individual patients. In large part this is because there has been insufficient study of the factor, especially prospective evaluations of the factor. Unfortunately this has resulted in the premature use of this information under the general rubric that patients with a poor prognosis deserve more treatment in spite of the fact that there may be no benefit from that therapy in the poor prognostic group.

prognostic predictive cut point c-erbB2 estrogen receptor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Henderson IC, Canellos GP: Cancer of the breast: the past decade. N Engl J Med 302:17-30/78–90, 1980Google Scholar
  2. 2.
    Sasaki GH, Leung BS, Fletcher WS: LevoDopa test and estrogen receptor assay in prognosticating responses of patients with advanced cancer of the breast to endocrine therapy. Ann Surg 183:392-396, 1976Google Scholar
  3. 3.
    Sluyser M, Van Nie R: Estrogen receptor content and hormone-responsiveness of growth of mouse mammary tumors. Cancer Res 34:3253-3257, 1974Google Scholar
  4. 4.
    Byar D, Sears M, McGuire W: Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer 15:299-310, 1979Google Scholar
  5. 5.
    Cooke T, George D, Shields R, Maynard P, Griffiths K: Oestrogen receptors and prognosis in early breast cancer. Lancet i:995-997, 1979Google Scholar
  6. 6.
    Fletcher W, Leung B, Davenport C: The prognostic significance of estrogen receptors in human breast cancer. Am J Surg 135:372-374, 1978Google Scholar
  7. 7.
    Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44:671-675, 1979Google Scholar
  8. 8.
    Holdaway IM, Mountjoy KG: Progesterone and oestrogen receptors in human breast cancer. Austr NZ J Med 8:630-638, 1978Google Scholar
  9. 9.
    Kern WH: Morphologic and clinical aspects of estrogen receptors in carcinoma of the breast. Surg Gynecol Obstet 148:240-242, 1979Google Scholar
  10. 10.
    Knight WA III, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669-4671, 1977Google Scholar
  11. 11.
    Lippman ME, Allegra JC, Thompson EG, Simon R, Barlock A, Green L, Huff KK, Do HMT, Aitken SC, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223-1228, 1978Google Scholar
  12. 12.
    Hayes D: Serum (circulating) tumor markers for breast cancer. Rec Results Cancer Res 140:101-131, 1996Google Scholar
  13. 13.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 235:177-182, 1987Google Scholar
  14. 14.
    Spiegel D, Bloom JR, Kraemer HC, Gottheil E: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 2:888-891, 1989Google Scholar
  15. 15.
    Kogon MM, Biswas A, Pearl D, Carlson RW, Spiegel D: Effects of medical and psychotherapeutic treatment on the survival of women with metastatic breast carcinoma. Cancer 80:225-230, 1997Google Scholar
  16. 16.
    Spiegel D: Cancer and depression [review]. Br J Psych Suppl 30:109-116, 1996Google Scholar
  17. 17.
    Gasparini G, Bevilacqua P, Dal Fior S, Panizzoni GA, Favretto S, Visona A, Meli S: Characterization of node-negative breast cancer by clinico-pathologic and biologic factors. Anticancer Res 10:205-208, 1990Google Scholar
  18. 18.
    Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71–85, 1992Google Scholar
  19. 19.
    Henderson IC: Adjuvant systemic therapy for early breast cancer. Cancer 74:401-409, 1994Google Scholar
  20. 20.
    Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996Google Scholar
  21. 21.
    Fisher B, Redmond C, Fisher ER, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6:1076-1087, 1988Google Scholar
  22. 22.
    Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courriere P, Millon R, Asselain B: Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 73:1545-1551, 1996Google Scholar
  23. 23.
    Osborne CK: Receptors. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases, Second Edition. Lippincott, Philadelphia, 1991, pp 301-325Google Scholar
  24. 24.
    Press M, Hung G, Godolphin W, Slamon D: Sensitivity of HER2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994Google Scholar
  25. 25.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989Google Scholar
  26. 26.
    Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120-1128, 1989Google Scholar
  27. 27.
    Thor A, Schwartz L, Koerner F, Edgerton S, Skates S, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, Wood WC: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49:7147-7152, 1989Google Scholar
  28. 28.
    Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin H, Isola J: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991Google Scholar
  29. 29.
    Lovekin C, Ellis I, Locker A, Robertson J, Bell J, Nicholson R, Gullick W, Elston C, Blamey R: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439-443, 1991Google Scholar
  30. 30.
    McCann A, Dervan P, O'Regan M, Codd M, Gullick W, Tobin B, Carney D: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51:3296-3303, 1991Google Scholar
  31. 31.
    Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992Google Scholar
  32. 32.
    Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam D-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, Senn H-J: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992Google Scholar
  33. 33.
    Noguchi M, Koyasaki N, Ohta N, Kitagawa H, Earashi M, Thomas M, Miyazaki I, Mizukami Y: c-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 69:2953-2960, 1992Google Scholar
  34. 34.
    Tanner B, Freidberg T, Itze M, Beck T, Oesch F, Knapstein P-G: c-erbB-2 oncogene expression in breast carcinoma: analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters. Gynecol Oncol 47:228-233, 1992Google Scholar
  35. 35.
    Yuan J, Hennessy C, Givan A, Corbett I, Henry J, Sherbet G, Lennard T: Predicting outcome for patients with node negative breast cancer; a comparative study of the value of flow cytometry and cell image analysis for determination of DNA ploidy. Br J Cancer 65:461-465, 1992Google Scholar
  36. 36.
    Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S: Prognostic significance of c-erbB-2 expression in node-negative breast cancer. Br J Cancer 67:625-629, 1993Google Scholar
  37. 37.
    Press M, Pike M, Chazin V, Hung F, Udove J, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson M, Slamon D: Her2-neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993Google Scholar
  38. 38.
    Gasparini G, Gullick W, Maluta S, Palma P, Caffo O, Leonardi E, Boracchi P, Pozza F, Lemoine N, Bevilacqua P: c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma — an immunocytochemical study. Eur J Cancer 30A:16-22, 1994Google Scholar
  39. 39.
    Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco A, De Placido S: c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708, 1996Google Scholar
  40. 40.
    Molland J, Barraclough B, Gebski V, Milliken J, Bilous M: Prognostic significance of c-erbB-2 oncogene in axillary node-negative breast cancer. Aust NZ J Surg 66:64-70, 1996Google Scholar
  41. 41.
    Andrulis I, Bull S, Blackstein M, et al: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16:1340-1349, 1998Google Scholar
  42. 42.
    Sjögren S, Inganäs M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469, 1998Google Scholar
  43. 43.
    Giai M, Roagna R, Ponzone R, de Bortoli M, Dati C, Sismondi P: Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 14:1441-1450, 1994Google Scholar
  44. 44.
    Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre J: The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 35:283-291, 1995Google Scholar
  45. 45.
    Borg Å, Tandon A, Sigurdsson H, Clark G, Fernö M, Fuqua S, Killander D, McGuire W: Her2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50:4332-4337, 1990Google Scholar
  46. 46.
    Têtu B, Brisson J: Prognostic significance of HER2/neu oncoprotein expression in node-positive breast cancer. Cancer 73:2359-2365, 1994Google Scholar
  47. 47.
    Muss HB, Thor A, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994Google Scholar
  48. 48.
    Hartmann L, Ingle J, Wold L, Farr GH J, Grill J, Su J, Maihle N, Krook J, Witzig T, Roche P: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 74:2956-2963, 1994Google Scholar
  49. 49.
    Tsuda H, Sakamaki C, Tsugane S, Fukutomi T, Hirohashi S: A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat 48:21-32, 1998Google Scholar
  50. 50.
    Lippman ME, Weisenthal LM, Paik SM, Nagourney RA, Kern DH: erbB-2 positive specimens from previously-untreated breast cancer patients have in vitro drug resistance profiles which resemble profiles of specimens obtained from patients who have previously failed combination chemotherapy. Proc ASCO 9:24, 1990Google Scholar
  51. 51.
    Thor A, Budman D, Berry D, Muss H, Kute T, Barcos M, Cirrincione C, Edgerton S, Weiss R, Ferree C, Allred C, Wood W, Frei E III, Henderson I, Norton L, Liu E: Selecting patients for higher dose adjuvant CAF: c-erbB-2, p53, dose and dose intensity in stage II, node+ breast cancer (CALGB 8869 and 8541). Proc ASCO 16:A452, 1997Google Scholar
  52. 52.
    Howell A, Harland RNL, Bramwell VHC, Swindell R, Barnes DM, Redford J, Wilkinson MJS, Crowther D, Sellwood RA: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet i:588-591, 1984Google Scholar
  53. 53.
    Fisher ER, Gregorio R, Redmond C, Dekker A, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). Am J Clin Pathol 65:21-30, 1976Google Scholar
  54. 54.
    Fisher E, Swamidoss S, Lee C, Rockette H, Redmond C, Fisher B: Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 42:2025-2031, 1978Google Scholar
  55. 55.
    Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52:1551-1557, 1983Google Scholar
  56. 56.
    Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW: Axillary micro-and macrometastases in breast cancer. Ann Surg 194:585-591, 1981Google Scholar
  57. 57.
    Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Rasmussen BB, Rose C: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49:6008-6014, 1989Google Scholar
  58. 58.
    Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322:297-302, 1990Google Scholar
  59. 59.
    Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SAW, Hilsenbeck SH, Chamness GC, Osborne CK: Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12:467-474, 1994Google Scholar
  60. 60.
    Rockette HE, Caplan RJ: Heterogeneous treatment effects — strategies for subgroup analysis in clinical trials. Rec Results Cancer Res 111:49-54, 1988Google Scholar
  61. 61.
    Hilsenbeck SG, Ravdin PM, de Moor CA, Osborne CK, Clark GM: Paradoxical decreases in prognostic utility as datasets mature: time-dependent lack of proportional hazards in prognostic factors in primary breast cancer [abstract]. Breast Cancer Res Treat 37:35, 1996Google Scholar
  62. 62.
    Hilsenbeck S, Clark G, McGuire W: Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 22:197-206, 1992Google Scholar
  63. 63.
    McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 326:1756-1761, 1992Google Scholar
  64. 64.
    Clark G, Hilsenbeck S, Ravdin P, Di Laurentiis M, Osborne C: Prognostic factors: Rationale and methods of analysis and integration. Breast Cancer Res Treat 32:105-112, 1994Google Scholar
  65. 65.
    Henderson IC: Prognostic factors. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases (2nd ed). Lippincott, Philadelphia, 1991, pp 332-346Google Scholar
  66. 66.
    Levine M, Browman G, Gent M, Roberts R, Goodyear M: When is a prognostic factor useful?: a guide for the perplexed. J Clin Oncol 9:348-356, 1991Google Scholar
  67. 67.
    McGuire WL, Tandon AK, Allred C, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006-1015, 1990Google Scholar
  68. 68.
    Gasparini G, Pozza F, Harris A: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993Google Scholar
  69. 69.
    Koenders P, Beex L, Kienhui C, Kloppenborg P, Benraad T: Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat 25:21-27, 1993Google Scholar
  70. 70.
    Seshadri R, McLeay W, Horsfall D, McCaul K: Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer. Int J Cancer 69:23-27, 1996Google Scholar
  71. 71.
    Pujol P, Maudelonde T, Daures J-P, Rouanet P, Brouillet J-P, Pujol H, Rochefort H: A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 71:2006-2012, 1992Google Scholar
  72. 72.
    Ciocca D, Clark G, Tandon A, Fuqua S, Welch W, McGuire W: Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer. J Natl Cancer Inst 85:570-574, 1993Google Scholar
  73. 73.
    Ravdin PM, Clark GM: A practical application of neural network analysis for predicting outcome of individual breast cancer patients. Breast Cancer Res Treat 22:285-293, 1992Google Scholar
  74. 74.
    Ravdin PM, Clark GM, Hilsenbeck SG, Owens MA, Vendely P, Pandian MR, McGuire WL: A demonstration that breast cancer recurrence can be predicted by neural network analysis. Breast Cancer Res Treat 21:47-53, 1992Google Scholar
  75. 75.
    Masters JRW, Camplejohn RS, Millis RR, Rubens RD: Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer. Br J Cancer 55:455-457, 1987Google Scholar
  76. 76.
    Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81:1383-1387, 1989Google Scholar
  77. 77.
    Fisher ER, Redmond C, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Cancer Project: VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation. Cancer 51:181-191, 1983Google Scholar
  78. 78.
    Hietanen P, Blomqvist C, Wasenius VM, Niskanen E, Franssila K, Nordling S: Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 71:1029-1032, 1995Google Scholar
  79. 79.
    Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H, Vielh P: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77:292-300, 1996Google Scholar
  80. 80.
    Kute TE, Quadri Y, Muss H, Zbieranski N, Cirrincione C, Berry DA, Barcos M, Thor AP, Liu E, Koerner F, et al: Flow cytometry in node-positive breast cancer: Cancer and Leukemia Group B protocol 8869. Cytometry 22:297-306, 1995Google Scholar
  81. 81.
    Sulkes A, Livingston RB, Murphy WK: Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 62:513-515, 1979Google Scholar
  82. 82.
    Silvestrini R, Daidone MG, Valagussa P, Salvadori B, Rovini D, Bonadonna G: Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat Rep 71:375-379, 1987Google Scholar
  83. 83.
    Clark GM, Mathieu MC, Owens MA, Dressler LG, Eudey L, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff MD, et al: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10:428-432, 1992Google Scholar
  84. 84.
    Bonadonna G, Valagussa P, Tancini G, Rossi A, Brambilla C, Zambetti M, Bignami P, Di Fronzo G, Silvestrini R: Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr 1:45-49, 1986Google Scholar
  85. 85.
    Dressler LG, Eudey L, Gray R, Tormey DC, McGuire WL, Gilchrist KW, Clark GM, Osborne CK, Mansour EG, Abeloff MD: Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: Preliminary analysis of an Intergroup study (INT 0076). JNCI Monographs 11:167-72, 1992Google Scholar
  86. 86.
    O'Reilly SM, Barnes DM, Camplejohn RS, Millis RR, Bartkova J, Rubens RD, Richards MA: The relationship between c-erbB-2 expression, S-phase fraction (SPF) and prognosis in breast cancer. Proc ASCO 9:18, 1990Google Scholar
  87. 87.
    Stal O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, Nordenskjold B: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A:2185-2190, 1995Google Scholar
  88. 88.
    Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbraglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J, Roth JA, Schinella RA, Schwartz IS, Wheeler JE: Interobserver reproducibility of histopathological features in Stage II breast cancer: An ECOG study. Breast Cancer Res Treat 5:3-10, 1985Google Scholar
  89. 89.
    Spyratos F, Briffod M, Tubiana-Hulin M, Andrieu C, Mayras C, Pallud C, Lasry S, Rouesse J: Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short-term follow-up. Cancer 69:470-475, 1992Google Scholar
  90. 90.
    O'Reilly SM, Richards MA: Is flow cytometry a useful investigation in breast cancer? Eur J Cancer 28:504-507, 1992Google Scholar
  91. 91.
    Briffod M, Spyratos F, Tubiana-Hulin M, Pallud C, Mayras C, Filleul A, Rouesse J: Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma: cytomorphologic changes, initial tumor ploidy, and tumor regression. Cancer 63:631-637, 1989Google Scholar
  92. 92.
    Barnes DM: Cyclin D1 expression and prognosis in mammary carcinoma. Proc AACR 37:A1418, 1996Google Scholar
  93. 93.
    Bates S, Parry D, Bonetta L, Vousden K, Dickson C, Peters G: Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene 9:1633-1640, 1994Google Scholar
  94. 94.
    Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69:92-99, 1996Google Scholar
  95. 95.
    McIntosh G, Anderson J, Milton I, Steward M, Parr A, Thomas M, Henry J, Angus B, Lennard T, Horne C: Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11:885-891, 1995Google Scholar
  96. 96.
    Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J: A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73:728-734, 1996Google Scholar
  97. 97.
    Pelosio P, Barbareschi M, Benoldi E, Marchetti A, Verderio P, Caffo O, Bevilacqua P, Borracchi P, Buttitta F, Barbazza R, Palma P, Gasparini G: Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 7:695-703, 1996Google Scholar
  98. 98.
    Seshadri R, Lee C, Hui R, McCaul K, Horsfall D, Sutherland R: Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 2:1174-1184, 1996Google Scholar
  99. 99.
    van Diest PJ, Michalides RJ, Jannink J, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP: Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 150:705-711, 1997Google Scholar
  100. 100.
    Silvestrini R, Benini E, Veneroni S, Daidone M, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14:1604-1610, 1996Google Scholar
  101. 101.
    Silvestrini R, Veneroni S, Benini E, Luisi A, Leutner M, Maucione A, Kenda R, Zucali R, Veronesi U: Expression of p53, glutathione S-transferase-1, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 89:639-45, 1997Google Scholar
  102. 102.
    van Slooten H-J, Clahsen P, van Dierendonck J, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van de Velde C, van de Vijver M: Expression of BCL-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Brit J Cancer 74:78-85, 1996Google Scholar
  103. 103.
    Lê M, Mathieu M, Llombart-Cussac A, Abd el Al H, Spielman M, Riou G: Prognostic value of bcl-2 expression in operable breast cancer patients. Proc ASCO 16:A483, 1997Google Scholar
  104. 104.
    Schroeder W, Biersterfield S, Zillessen S, Rath W: Epidermal growth factor receptor — immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res 17:2799-2802, 1997Google Scholar
  105. 105.
    Torregrosa D, Bolufer P, Lluch A, López J, Barragán E, Ruiz A, Guillem V, Munárriz B, García Conde J: Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chim Acta 262:99-119, 1997Google Scholar
  106. 106.
    Hawkins R, Tesdale A, Killen M, Jack W, Chetty U, Dixon J, Hulme M, Prescott R, McIntyre M, Miller W: Prospective evaluation of prognostic factors in operable breast cancer. Br J Cancer 74:1469-1478, 1996Google Scholar
  107. 107.
    Bolla M, Chedin M, Colonna M, Marron-Charrière J, Rostaing-Puissant B, Pasquier D, Panh M, Winckel P, Chambaz E: Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters. Breast Cancer Res Treat 29:265-270, 1994Google Scholar
  108. 108.
    Delarue JC, Friedman S, Mouriesse H, May-Levin F, Sancho-Garnier H, Contesso G: Epidermal growth factor receptor in human breast cancers: correlation with estrogen and progesterone receptors. Breast Cancer Res Treat 11:173-178, 1988Google Scholar
  109. 109.
    Fox SB, Smith K, Hollyer J, Greenhall M, Hastrich D, Harris AL: The epidermal growth factor receptor as a prognoste marker: Results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29:41-49, 1994Google Scholar
  110. 110.
    Gasparini G, Borazzio P, Bevilacqua P, Mezzetti M, Pozza F, Weidner N: A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res Treat 29:59-71, 1994Google Scholar
  111. 111.
    Klijn J, Look M, Portengen H, Alexieva-Figusch J, van Putten W, Foekens J: The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 29:73-83, 1994Google Scholar
  112. 112.
    Nicholson R, McClelland R, Gee J, Manning D, Cannon P, Robertson J, Ellis I, Blamey R: Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29:117-125, 1994Google Scholar
  113. 113.
    Noguchi M, Mizukami Y, Kinoshita K, Earashi M, Thomas M, Miyazaki I: The prognostic significance of epidermal growth factor receptor expression in breast cancer. Surg Today 24:889-894, 1994Google Scholar
  114. 114.
    Spyratos F, Martin P, Hacène K, Andrieu C, Romain S, Floiras J, Magdelènat H: Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay — a retrospective study. Breast Cancer Res Treat 29:85-95, 1994Google Scholar
  115. 115.
    Toi M, Tominaga T, Osaki A, Toge T: Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study. Breast Cancer Res Treat 29:51-58, 1994Google Scholar
  116. 116.
    Iwase H, Kobayashi S, Itoh Y, Kuzushima T, Yamashita H, Iwata H, Naito A, Yamashita T, Itoh K, Masaoka A: Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer. Breast Cancer Res Treat 28:215-221, 1993Google Scholar
  117. 117.
    Murray P, Barrett-Lee P, Travers M, Luqmani Y, Powles T, Coombes R: The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 67:1408-1412, 1993Google Scholar
  118. 118.
    Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T: Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 164:323-326, 1992Google Scholar
  119. 119.
    Sauer R, Schauer A, Rauschecker H, Schumacher M, Gatzemeier W, Sauerbrei W, Dunst J, Seegenschmiedt M, Marx D, et al: Breast preservation versus mastectomy in early breast cancer — 1991 update of the GBSG 1 — protocol and prognostic factors. Strahl Onkol 168:191-202, 1992Google Scholar
  120. 120.
    Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon J, Harris A: Epidermal growth factor receptor (EGFr); results of a 6-year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146-150, 1991Google Scholar
  121. 121.
    Toi M, Osaki A, Yamada H, Toge T: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27:977-980, 1991Google Scholar
  122. 122.
    Toi M, Nakamura T, Mukaida H, Wada T, Osaki A, Yamada H, Toge T, Niimoto M, Hattori T: Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 65:1980-1984, 1990Google Scholar
  123. 123.
    Lewis S, Locker A, Todd J, Bell J, Nicholson R, Elston C, Blamey R, Ellis I: Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 43:385-389, 1990Google Scholar
  124. 124.
    Spyratos F, Delarue J-C, Andrieu C, Lidereau R, Champéme M-H, Hacène K, Brunet M: Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17:83-89, 1990Google Scholar
  125. 125.
    Foekens J, Portengen H, van Putten W, Trapman A, Reubi J-C, Alexieva-Figusch J, Klijn J: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002-7009, 1989Google Scholar
  126. 126.
    Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treat 14:77-90, 1989Google Scholar
  127. 127.
    Harris AL, Nicholson S, Sainsbury JRC, Farndon J, Wright C: Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 34:123-131, 1989Google Scholar
  128. 128.
    Sainsbury JRC, Nicholson S, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) status. A clinically useful prognostic indicator in axillary node negative breast cancer [abstract]. Breast Cancer Res Treat 14:133, 1989Google Scholar
  129. 129.
    Costa S, Stamm H, Alemendral A, Ludwig H, Wyss R, Fabbro D, Ernst A, Takahashi A, Eppenberger U: Predictive value of EGF receptor in breast cancer. Lancet ii:1258, 1988Google Scholar
  130. 130.
    Nicholson S, Halcrow P, Sainsbury JRC, Angus B, Chambers P, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer 58:810-814, 1988Google Scholar
  131. 131.
    Rios MA, Macias A, Perez R, Lage A, Skoog L: Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res 8:173-176, 1988Google Scholar
  132. 132.
    Sainsbury JRC, Farndon JR, Needham GK, Harris AL, Malcolm AJ: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i:1398-1402, 1987Google Scholar
  133. 133.
    Schwartz L, Koerner F, Edgerton S, Sawicka J, Rio M-C, Bellocq J-P, Chambon P, Thor A: pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 51:624-628, 1991Google Scholar
  134. 134.
    Henry J, Piggott N, Mallick U, Nicholson S, Farndon J, Westley B, May F: pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 63:615-622, 1991Google Scholar
  135. 135.
    Hurlimann J, Gebhard S, Gomez F: Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 23:239-248, 1993Google Scholar
  136. 136.
    Luqmani YA, Ricketts D, Ryall G, Turnbull L, Law M, Coombes RC: Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor. Int J Cancer 54:619-623, 1993Google Scholar
  137. 137.
    Wilson Y, Rhodes M, Ibrahim N, Padfield C, Cawthorn S: Immunocytochemical staining of pS2 protein in fine-needle aspirate from breast cancer is an accurate guide to response to tamoxifen in patients aged over 70 years. Br J Surg 81:1155-1158, 1994Google Scholar
  138. 138.
    Soubeyran I, Quènal N, Coindre J-M, Bonichon F, Durand M, Wafflart J, Mauriac L: pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Brit J Cancer 74:1120-1125, 1996Google Scholar
  139. 139.
    Besse G, Kwiatkowski F, Gaillard G, Daver A, Dalifard I, Basuyau J, Brunelle P, Wafflart J, Angibeau R, Auvray E, Goussard J: Rôle prognostique de la protéine pS2 dans 1065 cas de cancer du sein. Étude multicentrique. Bull Cancer 81:289-296, 1994Google Scholar
  140. 140.
    MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM: Primary chemotherapy in invasive breast carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, sP2, and GST1. Br J Cancer 74:1458-1465, 1996Google Scholar
  141. 141.
    Predine J, Spyratos F, Prud'homme J, Andrieu C, Hacene K, Brunet M, Pallud C, Milgrom E: Enzymelinked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Cancer 69:2116-2123, 1992Google Scholar
  142. 142.
    Crombach G, Ingerhorst A, Göhring U-J, Scharl A, Möbus V, Schaeffer H-J: Expression of pS2 protein in breast cancer. Arch Gynecol Obstet 253:183-192, 1993Google Scholar
  143. 143.
    Göhring U-J, Scharl A, Ahr A: Immunohistochemical detection of receptors, proteases, tumour suppressor proteins and proliferating markers as prognostic indicators for primary breast cancer patients. Geburtsch Frauenheilk 56:177-183, 1996Google Scholar
  144. 144.
    Thor A, Koerner F, Edgerton S, Wood W, Stracher M, Schwartz L: pS2 expression in primary breast carcinomas: Relationship to clinical and histological features and survival. Breast Cancer Res Treat 21:111-119, 1992Google Scholar
  145. 145.
    Foekens J, Schmitt M, van Putten W, Peters H, Kramer M, Jänicke F, Klijn J: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658, 1994Google Scholar
  146. 146.
    Foekens J, Rio M-C, Seguin P, van Putten W, Fauque J, Nap M, Klijn J, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50:3832-3837, 1990Google Scholar
  147. 147.
    Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Bari M, Leon AE, Vinante O, Bruscagnin G: pS2 in breast cancer — alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 68:374-379, 1993Google Scholar
  148. 148.
    Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJR, Neoptolemos JP, Chan SY, Baker PR: Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 30A:5-11, 1994Google Scholar
  149. 149.
    Speiser P, Stolzechner J, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, Zeilliger R: pS2 protein status fails to be an independent prognostic factor in an average breast cancer population. Anticancer Res 14:2125-2130, 1994Google Scholar
  150. 150.
    Thompson A, Hawkins R, Elton R, Steel C, Chetty U, Carter D: pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer 68:93-96, 1993Google Scholar
  151. 151.
    Clahsen P, van de Velde C, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van de Broek L, Sahmoud T, van de Vijver M: p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 16:470-479, 1998Google Scholar
  152. 152.
    Formenti S, Dunnington G, Lenz H, Russell C, Silberman H, Spicer D, Groshen S, Watkins K, Muggia F: Original p53 status predicts for pathological response to 5-fluorouracil and radiation in locally advanced breast cancer. Proc ASCO 16:A590, 1997Google Scholar
  153. 153.
    Acenero M, González J, Ballesteros P: Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: Relation with epidemiological factors, histologic features and prognosis. Gen Diag Pathol 142:289-296, 1996Google Scholar
  154. 154.
    Eissa S, Khalifa A, El-Gharib A, Salah N, Mohamed M: Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer. Anticancer Res 17:1417-1424, 1997Google Scholar
  155. 155.
    Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Dalla Palma P, Harris A, Barbareschi M: Prognostic value of p21WAF21 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 2:1591-1599, 1996Google Scholar
  156. 156.
    Charpin C, Garcia S, Bouvier C, Andrac L, Devictor B, Lavaut M-N, Allasia C, Bonnier P, Piana L: Quantitative immunocytochemical assays on frozen sections of p53. Correlation to the follow-up of patients with breast carcinomas. Anat Pathol 106:640-646, 1996Google Scholar
  157. 157.
    Katoh A, Breier S, Stemmler N, Specht S, Blanock K, D'Amico F: p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease. Anticancer Res 16:1301-1304, 1996Google Scholar
  158. 158.
    Hou M-F, Huang T-J, Huang C-J, Huang Y-S, Hsieh J-S, Lin S-J: Expression of p53 protein and its prognostic significance in breast cancer patients. Kaohsiung J Med Sci 12:471-478, 1996Google Scholar
  159. 159.
    Regidor P, Regidor M, Callies R, Schindler A: Detection of p53 auto-antibodies in the sera of breast cancer patients with new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist? Eur J Gynaec Oncol 17:192-199, 1996Google Scholar
  160. 160.
    Silvestrini R, Benini E, Daidone M, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993Google Scholar
  161. 161.
    Willsher P, Pinder S, Robertson L, Nicholson R, Ellis I, Bell J, Blamey R, Green J, Robertson J: The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 16:927-930, 1996Google Scholar
  162. 162.
    Archer S, Eliopoulos A, Spandidos D, Barnes D, Ellis I, Blamey R, Nicholson R, Robertson J: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first-line hormonal therapy. Br J Cancer 72:1259-1266, 1995Google Scholar
  163. 163.
    Bland K, Konstadoulakis M, Vezeridis M, Wanebo H: Oncogene protein co-expression. Value of Ha-ras, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221:706-720, 1995Google Scholar
  164. 164.
    Daidone M, Silvestrini R, Benini E, Luisi A: Biologic variables could predict specific relapse types in node-negative breast cancer. Anticancer Res 15:1825, 1995Google Scholar
  165. 165.
    Elledge R, Gray R, Mansour E, Yu Y, Clark G, Ravdin P, Osborne C, Gilchrist K, Davidson N, Robert N, Tormey D, Allred D: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256, 1995Google Scholar
  166. 166.
    Göhring U-J, Scharl A, Heckel C, Ahr A, Crombach G: p53 protein in 204 patients with primary breast carcinoma — immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet 256:139-146, 1995Google Scholar
  167. 167.
    Jansson T, Inganäs M, Sjögren S, Norberg T, Lindgren A, Holmberg L, Bergh J: p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13:2745-2751, 1995Google Scholar
  168. 168.
    Kristen P, Müller JG, Caffier H: Prognostic relevance of p53 in node negative breast cancer. Anticancer Res 17:2869-2871, 1997Google Scholar
  169. 169.
    Mathieu M-C, Koscielny S, Bihan M-CL, Spielmann M, Arrigada R: No relation between p53 and response to chemotherapy [letter]. Lancet 345:1182, 1995Google Scholar
  170. 170.
    Veronese S, Saladini L, Cannone M, Gamacorta M: Biological parameters and prognosis in breast cancer. Anticancer Res 15:1827, 1995Google Scholar
  171. 171.
    Koechli O, Schauer G, Selfert B, Hornung R, Haller U, Eppenberger U, Mueller H: Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344:1647-1648, 1994Google Scholar
  172. 172.
    Noguchi M, Kitagawa H, Kinoshita K, Thomas M, Matsuo I, Saito Y, Mizakami Y, Nonomura A, Michigishi T, Nakamura S: The relationship of p53 protein and lymph node metastases in invasive breast cancer. Surg Today 24:512-517, 1994Google Scholar
  173. 173.
    Allred D, Clark G, Elledge R, Fuqua S, Brown R, Chamness G, Osborne C, McGuire W: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993Google Scholar
  174. 174.
    Barnes D, Dublin E, Fisher C, Levinson D, Millis R: Immunohistochemical detection of p53 protein in mammary carcinoma. An important new independent indicator of prognosis? Hum Pathol 24:469-476, 1993Google Scholar
  175. 175.
    Thorlacius S, Børresen A-L, Eyfjörd J: Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 53:1637-1641, 1993Google Scholar
  176. 176.
    Isola J, Visakorpi T, Holli K, Kallionemi O-P: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992Google Scholar
  177. 177.
    Poller D, Hutchings C, Galea M, Bell J, Nicholson R, Elston C, Blamey R, Ellis I: p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer 66:583-588, 1992Google Scholar
  178. 178.
    Thor A, Moore D, Edgerton S, Kawasaki E, Reihsaus E, Lynch H, Marcus J, Schwartz L, Chen L-C, Mayall B, Smith H: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992Google Scholar
  179. 179.
    Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S: Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82:835-840, 1991Google Scholar
  180. 180.
    Ostrowski J, Sawan A, Henry L, Wright C, Henry J, Henessy C, Lennard T, Angus B, Horne C: p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164:75-81, 1991Google Scholar
  181. 181.
    Chamness GC, Ruiz A, Fulcher L, Clark GM, McGuire WL: Stress response protein srp27 predicts recurrence in node-negative breast cancer. Breast Cancer Res Treat 12:130, 1988Google Scholar
  182. 182.
    Chamness GC, Ruiz A, Fulcher L, Clark G, Fuqua S, McGuire W: Estrogen-inducible heat shock protein hsp27 predicts recurrence in node-negative breast cancer. Proc AACR 30:252, 1989Google Scholar
  183. 183.
    Porter P, Malone K, Heagerty P, Alexander G, Gatti L, Firpo E, Daling J, Roberts L: Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3:222-225, 1997Google Scholar
  184. 184.
    Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galuzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer 57:1259-1263, 1997Google Scholar
  185. 185.
    Panel ATME: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14:2843-2877, 1996Google Scholar
  186. 186.
    Sastre-Garau X, Lacombe M, Jouve M, Véron M, Magdelénat H: Nucleoside diphosphate kinase/nm23 expression in breast cancer: lack of correlation with lymph node metastasis. Int J Cancer 50:533-538, 1992Google Scholar
  187. 187.
    Tokunaga Y, Urano T, Furukawa K, Kondo H, Kanematsu T, Shiku H: Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. Int J Cancer 55:66-71, 1993Google Scholar
  188. 188.
    Barnes R, Masood S, Barker E, Rosengard A, Coggin D, Crowell T, King C, Porter-Jordan K, Wargotz E, Liotta L, Steeg P: Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol 139:245-250, 1991Google Scholar
  189. 189.
    Hennessy C, Henry JA, May FEB, Westley BR, Angus B, Lennard TWJ: Expression of the antimetastatic gene nm23 in human breast cancer: An association with good prognosis. J Natl Cancer Inst 83:281-285, 1991Google Scholar
  190. 190.
    Bevilacqua G, Sobel M, Liotta L, Steeg P: Association of low nm23 RNA levels in human primary infiltrating ductal carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 49:5185-5190, 1989Google Scholar
  191. 191.
    Granata G, Coradini D, Cappelletti V, DiFronzo G: Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 27:970-972, 1991Google Scholar
  192. 192.
    Han S, Yun I, Noh D, Choe K, Song S, Chi J: Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 65:22-27, 1997Google Scholar
  193. 193.
    Namer M, Ramaioli A, Fontana X, Etienne M-C, Hery M, Jourlait A, Milano G, Frenay M, François E, Laplaus F: Prognostic value of total cathepsin D in breast tumors. A possible role in selection of chemoresistant patients. Breast Cancer Res Treat 19:85-93, 1991Google Scholar
  194. 194.
    Kute T, Shao Z-M, Sugg N, Long R, Russell G, Case L: Cathepsin D as a prognostic indicator for node negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52:5198-5203, 1992Google Scholar
  195. 195.
    Spyratos F, Martin P-M, Hacène K, Romain S, Andrieu C, Ferrero-Poüs M, Deytieux S, Doussal VL, Tubiana-Hulin M, Brunet M: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84:1266-1272, 1992Google Scholar
  196. 196.
    Henry JA, McCarthy AL, Angus B, Westley BR, May FEB, Nicholson S, Horne CHW: Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer: An immunohistochemical study. Cancer 65:265-271, 1990Google Scholar
  197. 197.
    Alex G, Neises M, Lenz F, Melchert F: The value of new prognostic factors for the prediction of diseasefree interval for women with primary breast cancer in comparison with histopathological variables. Eur J Cancer 33:A 896, 1997Google Scholar
  198. 198.
    Itoh Y, Kobayashi S, Iwase H, Yamashita H, Kuzushima T, Iwata H, Yamashita T, Naitoh A, Itoh K, Masaoka A: Clinical significance of cathepsin D assay in breast cancer tissues. J Surg Oncol 60:221-226, 1995Google Scholar
  199. 199.
    Eng Tan P, Benz C, Dollbaum C, Moore D, Edgerton S, Zava D, Thor A: Prognostic value of cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol 5:329-336, 1994Google Scholar
  200. 200.
    Castiglioni T, Merino M, Elsner B, Lah T, Sloane B, Emmert-Buck M: Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Human Pathol 25:857-862, 1994Google Scholar
  201. 201.
    Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993Google Scholar
  202. 202.
    Charpin C, Garcia S, Bouvier C, Martinin F, Lavaut M, Allasia C, Bonnier P, Andrac L: Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival. J Clin Pathol 50:586-590, 1997Google Scholar
  203. 203.
    Göhring U-J, Scharl A, Thelen U, Crombach G, Titus B-R: Prognostic value of cathepsin D in breast cancer: comparison in immunohistochemical and immunoradiometric detection methods. J Clin Pathol 49:57-64, 1996Google Scholar
  204. 204.
    Visscher D, Sarkar F, LoRusso P, Sakr W, Ottosen S, Wykes S, Crissman J: Immunohistochemical evaluation of invasion-associated proteases in breast carcinoma. Mod Pathol 6:302-306, 1993Google Scholar
  205. 205.
    Winstanley J, Leinster S, Cooke T, Westley B, Platt-Higgins A, Rudland P: Prognostic significance of cathepsin D in patients with breast cancer. Br J Cancer 67:767-772, 1993Google Scholar
  206. 206.
    Romain S, Muracciole X, Varette I, Bressac C, Brandone H, Martin P: La cathepsine-D: un facteur prognostique indèpendant dans le cancer du sein. Bull Cancer 77:439-447, 1990Google Scholar
  207. 207.
    Jänicke F, Schmitt M, Graeff H: The urokinase-type plasminogen activator (u-PA) is related to early relapse in breast cancer. Br J Cancer s62:5, 1990Google Scholar
  208. 208.
    Grøndahl-Hansen J, Christensen I, Rosenquist C, Brünner N, Mouridsen H, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521, 1993Google Scholar
  209. 209.
    Harbeck N, Thomssen C, Henselmann B, Dettmar P, Prechtl A, Pache L, Kuhn W, Höfler H, Jänicke F, Schmitt M, Graef H: Long-term prognostic impact of PAI-1 in primary breast cancer confirmed by six-year median follow-up. Eur J Cancer 33:A877, 1997Google Scholar
  210. 210.
    Schmitt M, Goretzki L, Jänicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H: Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta 50:731-741, 1991Google Scholar
  211. 211.
    Duffy M, Duggan C, Maguire T, McDermott E, O'Higgins N: Clinical significance of urokinase plasminogen activator and its receptor in breast cancer. Eur J Cancer 33:A879, 1997Google Scholar
  212. 212.
    Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer 62:531-533, 1988Google Scholar
  213. 213.
    Klijn J, Berns E, Look M, van Gelder MM, Foekens J: Relationship of p53, uPA, pS2, EGF-R, and c-erbB-2, with response to systemic treatment in recurrent breast cancer patients. Eur J Cancer 33:A886, 1997Google Scholar
  214. 214.
    Athanassiadou P, Athanassiades P, Kyrkou K, Giahnaki E, Giannioti E, Nanas S: Expression of vimentin and epidermal growth factor receptor in effusions from patients with breast cancer; correlation with oestrogen and progesterone receptor status. Cytopathology 4:91-98, 1993Google Scholar
  215. 215.
    Domagala W, Striker G, Szadowska A, Dukowicz A, Harezga B, Osborn M: p53 protein and vimentin in invasive ductal NOS breast carcinoma — relationship with survival and sites of metastases. Eur J Cancer 30A:1527-1534, 1994Google Scholar
  216. 216.
    Chenard M-P, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq J-P, Duffy M: High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 69:448-451, 1996Google Scholar
  217. 217.
    Daidone M, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini A, Garbisa S, Liotta L, Grigioni W: Laminin receptors, collagenase IV and prognosis in node negative breast cancers. Int J Cancer 48:529-532, 1991Google Scholar
  218. 218.
    Duffy M, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennelly J, Tschesche H: Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer 71:1025-1028, 1995Google Scholar
  219. 219.
    Linder C, Engel G, Auer G, Strander H, Linder S: Distribution of stromelysin-3 mRNA transcripts and microvessels in human breast carcinomas. Breast Cancer Res Treat 42:207-213, 1997Google Scholar
  220. 220.
    Russo A, Bazan V, Morello V, Tralongo V, Nagar C, Nuara R, Dardanoni G, Bazan P, Tomasino R: Vimentin expression, proliferating cell nuclear antigen and flow cytometric factors: prognostic role in breast cancer. Anal Quant Cyt Hist 16:364-374, 1994Google Scholar
  221. 221.
    Seshadri R, Raymond W, Leong A, Horsfall D, McCaul K: Vimentin expression is not associated with poor prognosis in breast cancer. Int J Cancer 67:353-356, 1996Google Scholar
  222. 222.
    Stonelake P, Hail C, Jevons C, Baker P, Baker P: Proteinases and other prognostic markers in breast cancer. Br J Cancer 69:A83, 1994Google Scholar
  223. 223.
    Perin T, Canzonieri V, Massarut S, Bidoli E, Rossi C, Roncadin M, Carbone A: Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur J Cancer 12A:1148-1155, 1996Google Scholar
  224. 224.
    Pellegrini R, Martignone S, Tagliabue E, Belotti D, Bufalino R, Cascinelli M, Mènard S, Colnaghi M: Prognostic significance of laminin production in relation with its receptor expression in human breast carcinomas. Breast Cancer Res Treat 35:195-199, 1995Google Scholar
  225. 225.
    Martignone: Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst 85:398-402, 1993Google Scholar
  226. 226.
    Marques LA, Franco EL, Torloni H, Brentani MM, Baptista da Silva-Neto J, Brentani RR: Prognostic value of laminin receptor expression in breast cancer survival. Cancer Res 50:1479-1483, 1990Google Scholar
  227. 227.
    Colnaghi M, Cascinelli N, Rilke F, Ménard S, Bufalino R, Andreola S, Martignone S, Greco M, Mascheroni L, Testori A: Predicting potential of c-erbB-2 oncoprotein and laminin receptor expression on primary breast cancer. Eur J Cancer 29Asuppl 6:S31, 1993Google Scholar
  228. 228.
    Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis — Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991Google Scholar
  229. 229.
    Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124, 1992Google Scholar
  230. 230.
    Gasparini G, Fox SB, Verderio P: Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 2:1191-1198, 1996Google Scholar
  231. 231.
    Gasparini G: Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the Vicenza studies. Eur J Cancer 32A:2485-2493, 1996Google Scholar
  232. 232.
    Axelsson K, Ljung B-M, Moore D, Thor A, Chew K, Edgerton S, Smith H, Mayall B: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 87:997-1007, 1995Google Scholar
  233. 233.
    Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred E, Moore D, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1888, 1992Google Scholar
  234. 234.
    Weidner N, Folkman J: Tumor vascularity as a prognostic factor in cancer. Principles and Practice of Oncology Updates 11:24, 1997Google Scholar
  235. 235.
    Vermeulen P, Libura J, Libura M, Hellemans P, Van Marck E, van Oosterom A, Dirix L: Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma [letter]. J Natl Cancer Inst 87:1797-1798, 1995Google Scholar
  236. 236.
    Fox S, Gatter K, Altman D, Leek R, Harris A: Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma [letter]. J Natl Cancer Inst 87:1798-1799, 1995Google Scholar
  237. 237.
    Gasparini G: Re: Tumor angiogenesis as a prognostic assay in invasive ductal carcinoma [Letter]. J Natl Cancer Inst 87:1799-1801, 1995Google Scholar
  238. 238.
    Axelsson K, Ljung B-M, Chew K, Mayall B, Moore D, Smith H, Thor A, Edgerton S: Re: Tumor angiogenesis as a prognostic assay in invasive ductal carcinoma [letter]. J Natl Cancer Inst 87:1801-1802, 1995Google Scholar
  239. 239.
    Heimann R, Ferguson D, Powers C, Recant W, Weichselbaum R, Hellman S: Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 88:1764-1769, 1996Google Scholar
  240. 240.
    Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139-145, 1997Google Scholar
  241. 241.
    Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371-374, 1993Google Scholar
  242. 242.
    Bosari S, Lee A, DeLellis R, Wiley B, Heatley G, Silverman M: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761, 1992Google Scholar
  243. 243.
    Vartanian R, Weidner N: Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 144:1188-1194, 1994Google Scholar
  244. 244.
    Weidner N, Gasparini G: Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients. Breast Cancer Res Treat 29:97-107, 1994Google Scholar
  245. 245.
    Toi M, Inada K, Suzuki H, Tominaga T: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with endothelial growth factor expression. Breast Cancer Res Treat 36:193-204, 1995Google Scholar
  246. 246.
    Siitonen S, Haapasalo H, Rantala I, Helin H, Isola J: Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Mod Pathol 8:745-752, 1995Google Scholar
  247. 247.
    McCulloch P, Choy A, Martin L: Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 346:1334-1335, 1995Google Scholar
  248. 248.
    Ellis L, Fidler I: Angiogenesis and breast cancer metastasis. Lancet 346:388-389, 1995Google Scholar
  249. 249.
    Goulding H, Rashid N, Robertson J, Bell J, Elston C, Blamey R, Ellis I: Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Hum Pathol 26:1196-1200, 1995Google Scholar
  250. 250.
    Relf M, LeJeune S, Scott P, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris A: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969, 1997Google Scholar
  251. 251.
    Salvén P, Joensuu H, Heikkilä P, Matikainen M-T, Wasenius V-M, Alanko A, Alitalo K: Endothelial TIE growth factor provides antigenic marker for assessment of breast cancer angiogensis. Br J Cancer 74:69-72, 1996Google Scholar
  252. 252.
    Toi M, Hoshima S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85:1045-1049, 1994Google Scholar
  253. 253.
    Lee W-J, Chu J-S, Houng S-J, Chung M-F, Wang S-M, Chen K-M: Breast cancer angiogenesis: A quantitative morphologic and doppler imaging study. Ann Surg Oncol 2:246-251, 1995Google Scholar
  254. 254.
    Gasparini G, Barbareschi M, Boracchi P, Bevilacqua P, Verderio P, Dalla Palma P, Ménard S: 67-kDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer. Int J Cancer 60:604-610, 1995Google Scholar
  255. 255.
    Obermair A, Kurtz C, Czerwenka K, Thoma M, Kaider A, Wagner T, Gitsch G, Selveda P: Microvessel density and vessel invasion in lymph-node-negative breast cancer: Effect on recurrence-free survival. Int J Cancer 62:126-131, 1995Google Scholar
  256. 256.
    Kato T, Kinura T, Miyakawa R, Tanaka S, Fujii A, Yamamoto K, Kameoka S, Hamano K, Kawakami M, Aiba M: Clinicopathologic study of angiogenesis in Japanese patients with breast cancer. World J Surg 21:49-56, 1997Google Scholar
  257. 257.
    Paulsen T, Aas T, Borresen A-L, Varhaug J, Lønning P, Akslen L: Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. Int J Cancer 74:138-140, 1997Google Scholar
  258. 258.
    Morphopolous G, Pearson M, Ryder W, Howell A, Harris M: Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. J Pathol 180:44-49, 1996Google Scholar
  259. 259.
    Simpson J, Ahn C, Battifora H, Esteban J: Endothelial area as a prognostic indicator for invasive breast carcinoma. Cancer 77:2077-2085, 1996Google Scholar
  260. 260.
    Bevilacqua P, Barbareschi M, Verderio P, Boracchi P, Caffo O, Dalla Palma P, Meli S, Weidner N, Gasparini G: Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma — results of a multiparametric study. Breast Cancer Res Treat 36:205-217, 1995Google Scholar
  261. 261.
    Costello P, McCann A, Carney D, Dervan P: Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 26:1181-1194, 1995Google Scholar
  262. 262.
    Fox S, Leek R, Weekes M, Whitehouse R, Gatter K, Harris A: Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177:275-283, 1995Google Scholar
  263. 263.
    Karaiosifidi H, Kouri E, Arvaniti H, Sfikas S, Vasilaros S: Tumor angiogenesis in node-negative breast cancer: Relationship with relapse-free survival. Anticancer Res 16:4001-4002, 1996Google Scholar
  264. 264.
    Fox S, Turner G, Leek R, Whitehouse R, Gatter K, Harris A: The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. Breast Cancer Res Treat 36:219-226, 1995Google Scholar
  265. 265.
    Gasparini G, Harris A: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13:765-782, 1995Google Scholar
  266. 266.
    Hall N, Fish D, Hunt N, Goldin R, Guillou P, Monson J: Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1:223-229, 1992Google Scholar
  267. 267.
    Ogawa Y, Chung Y-S, Nakata B, Takatsuka S, Maede K, Sawade T, Kato Y, Yoshikawa K, Sakurai M, Sowa M: Microvessel quantitation in invasive breast cancer: staining for factor VIII-related antigen. Br J Cancer 71:1297-1301, 1995Google Scholar
  268. 268.
    Liotta L, Saidel G, Kleinerman J: The significance of intravascular tumor cell clumps in the metastatic process. Cancer Res 36:889-894, 1976Google Scholar
  269. 269.
    Smolin G, Hyundiuk R: Lymphatic drainage from vascularized rabbit cornea. Am J Opthamol 72:147-151, 1971Google Scholar
  270. 270.
    Viens P, Bertolucci F, Sun Z, Penault Llorca F, Bardou V, Geneix J, Jacquemier J: p53 overexpression and tumor angiogenesis are associated with treatment failure in women with breast cancer treated by a standard dose adjuvant chemotherapy. Proc AACR 38:A1579, 1997Google Scholar
  271. 271.
    Barnes D, Dublin E, Smith P, Miles DW, Rubens RD: Stabilized p53 protein and outcome following adjuvant CMF in 277 women with mammary carcinoma. Proc AACR 38:A1581, 1997Google Scholar
  272. 272.
    Fox S, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse R, Bicknell R, Gatter K, Harris A: The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 73:275-280, 1996Google Scholar
  273. 273.
    Obermair A, Kucera E, Mayerhofer K, Speiser P, Seifert M, Czerwenka K, Kaider A, Leodolter S, Kainz C, Zeillinger R: Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 74:455-458, 1997Google Scholar
  274. 274.
    Dirix L, Vermeulen P, Pawinski A, Prové A, Benoy I, de Pooler C, Martin M, van Oosterom A: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76:238-243, 1997Google Scholar
  275. 275.
    Bonneterre J, Peyrat J, Beuscart R, Demaille A: Prognostic significance of insulin-like growth factor-1 receptors in human breast cancer. Cancer Res 50:6931-6935, 1990Google Scholar
  276. 276.
    Railo M, van Smitten K, Pekonen F: The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A:307-311, 1994Google Scholar
  277. 277.
    Berns E, Klijn J, van Staveren I, Portengen H, Foekens J: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52:1036-1039, 1992Google Scholar
  278. 278.
    Liu F-F, Miller N, Levin W, Zanke B, Cooper B, Henry M, Sherrar M, Pintlie M, Hunt J, Hill R: The potential role of HSP70 as an indicator of response to radiation and hyperthermia treatments for recurrent breast cancer. Int J Hypertherm 12:197-208, 1996Google Scholar
  279. 279.
    Love S, King R: A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 69:743-748, 1994Google Scholar
  280. 280.
    Tandon AK, Clark GM, Chamness GC, Fuqua SAW, Welch WJ, Riehl RM, McGuire WL: Heat shock/stress response proteins: biological and clinical significance in breast cancer. Proc ASCO 9:23, 1990Google Scholar
  281. 281.
    Solomayer E-F, Diel I, Gollan C, Wallweiner D, Gisecke F, Kaul S, Basert G: Tumor cell detection in breast cancer patients before and after neoadjuvant chemotherapy. Eur J Cancer 33:A342, 1997Google Scholar
  282. 282.
    Depenni R, Federico M, Morselli M, Luppi M, Cagossi K, Barbieri F, Torelli G, Silingardi V: Detection of circulating breast cancer cells by RTPCR of maspin gene: the mobilising effect of conventional chemotherapy. Proc ASCO 16:A487, 1997Google Scholar
  283. 283.
    Diel I, Gollan C, Wallweiner D, Basert G: Prognostic impact of minimal residual disease in patients with early breast cancer. Eur J Cancer 33:A340, 1997Google Scholar
  284. 284.
    Fox S, Leek R, Bliss J, Mansi J, Gusterson B, Gatter K, Harris A: Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 89:1044-1049, 1997Google Scholar
  285. 285.
    Mansi J, Berger U, Easton D, MacDonnell T, Redding W, Gazet J-C, McKinna A, Powles T, Coombes C: Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J 295:1093, 1987Google Scholar
  286. 286.
    Ménard S, Squicciarini P, Luini A, Sacchini V, Rovini D, Tagliabue E, Veronesi P, Salvadori B, Veronesi U, Colnaghi M: Immunodetection of bone marrow metastases in breast carcinoma patients and its correlation with primary tumour prognostic features. Br J Cancer 66:1126-1129, 1994Google Scholar
  287. 287.
    Marcus J, Page D, Watson P, Narod S, Lenoir G, Lynch H: BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. Cancer 80:543-556, 1997Google Scholar
  288. 288.
    Jóhannsson O, Ranstam J, Borg Å, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 16:397-404, 1998Google Scholar
  289. 289.
    Krainer M, Silva-Arrieta S, Fitzgerald M, Shimada A, Ishioka C, Kanamaru R, MacDonald D, Unsal H, Finkelstein D, Bowcock A, Isselbacher K, Haber D: Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 336:1416-1421, 1997Google Scholar
  290. 290.
    Eisinger F, Lyonnet DS, Longy M, et al: Germ line mutation at BRCA1 affects histoprognostic grade in hereditary breast cancer. Cancer Res 56:471-474, 1996Google Scholar
  291. 291.
    Marcus J, Watson P, Page D, Narod S, Lenoir G, Tonin A, Linder-Stephenson L, Salerno G, Conway T, Lynch H: Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709, 1996Google Scholar
  292. 292.
    Lynch H, Marcus J, Watson P, Page D: Distinctive clinicopathological features of BRCA-1 linked hereditary breast cancer. Proc ASCO 13:A27, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • I. Craig Henderson
  • Anthony J. Patek

There are no affiliations available

Personalised recommendations